Skip to content
MedsAcross

Medicine

Griseofulvin 125 mg/5 mL oral suspension

Griseofulvin · Oral
Available on requestPrescription onlyUS FDAGeneric name

Griseofulvin 125 mg/5 mL oral suspension is a generic prescription medicine for oral use, made by 4 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F).

Key facts

Active ingredient (INN)
Griseofulvin
Brand
Sold under the generic name
Strength
125 mg/5 mL
Dosage form
Oral suspension
Route
Oral
Packs
120 mL, 118 mL and 1 more
Manufacturers
CiplaIndiaActavis PharmaChartwell RXCosette Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
D01AA08 Griseofulvin
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
2 March 2005
Identifiers
RxCUI 239238DailyMed set ID 67e3ba3c-77e1-43b5-a93c-5bf5e3855780, af318d5d-cc39-4a63-a590-b87c50f2694f, 9f7e4ecf-f992-42c5-81ea-91e6587b22a5 +1NDC 0713-0850, 0472-0013, 62135-968 +1Application ANDA065438, ANDA065394, ANDA065200 +1

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
120 mL in 1 bottle69097-361-08CiplaIndia6 March 2017
120 mL in 1 bottle0472-0013-04Actavis Pharma26 July 2007
120 mL in 1 bottle62135-968-41Chartwell RX26 August 2021
118 mL in 1 bottle, plastic0713-0850-04Cosette Pharmaceuticals1 November 2022

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Griseofulvin

Clinical summary

Griseofulvin is a tubulin inhibiting agent indicated for the treatment of ringworm infections, tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch). MedsAcross supplies Griseofulvin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Griseofulvin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Griseofulvin 125 mg/5 mL oral suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.